Search

Your search keyword '"Sahr, Natasha"' showing total 33 results
Start Over Author "Sahr, Natasha" Publication Year Range Last 50 years
33 results on '"Sahr, Natasha"'

2. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma

Author

Furman, Wayne L, Federico, Sara M, McCarville, Mary Beth, Shulkin, Barry L, Davidoff, Andrew M, Krasin, Matthew J, Sahr, Natasha, Sykes, April, Wu, Jianrong, Brennan, Rachel C, Bishop, Michael William, Helmig, Sara, Stewart, Elizabeth, Navid, Fariba, Triplett, Brandon, Santana, Victor M, Bahrami, Armita, Anthony, Gwendolyn, Yu, Alice L, Hank, Jacquelyn, Gillies, Stephen D, Sondel, Paul M, Leung, Wing H, and Pappo, Alberto S

Subjects
Clinical Trials and Supportive Activities, Neuroblastoma, Rare Diseases, Cancer, Neurosciences, Pediatric, Pediatric Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Child, Disease-Free Survival, Female, Gangliosides, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Killer Cells, Natural, Male, Progression-Free Survival, Prospective Studies, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma.Patients and methodsWe conducted a prospective nonrandomized, single-arm, two-stage, phase II clinical trial. Six courses of induction chemotherapy were coadministered with hu14.18K322A and followed with granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose IL2. Consolidation was performed with a busulfan/melphalan preparative regimen. An additional course of hu14.18K322A was administered with parent-derived natural killer cells, when available, during consolidation. Hu14.18K322A, GM-CSF, IL2, and isotretinoin were then administered. Secondary outcomes included reduced tumor volume and semiquantitative 123I-metaiodobenzylguanidine scoring [i.e., Curie scores (CS)] at the end of induction.ResultsForty-two patients received hu14.18K322A and induction chemotherapy. This regimen was well tolerated, with continuous-infusion narcotics adjusted to patient tolerance. Partial responses (PR) or better after the first two chemoimmunotherapy courses occurred in 32 patients [76.2%; 95% confidence interval (CI), 60.6-88.0]. This was accompanied by primary tumor volume reductions (median, -76%; range, -100% to 5%). Of 35 patients with stage IV disease who completed induction, 31 had end-of-induction CSs of 2 or less. No patients experienced progression during induction. Two-year event-free survival (EFS) was 85.7% (95% CI, 70.9-93.3).ConclusionsAdding hu14.18K322A to induction chemotherapy produced early PR or better in most patients, reduced tumor volumes, improved CSs at the end of induction, and yielded an encouraging 2-year EFS. These results, if validated in a larger study, may change the standard of care for children with high-risk neuroblastoma.

Published
2019

5. Supplementary Table S4 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents

Author

Gartrell, Jessica, primary, Mellado-Largarde, Marcia, primary, Clay, Michael R., primary, Bahrami, Armita, primary, Sahr, Natasha A., primary, Sykes, April, primary, Blankenship, Kaley, primary, Hoffmann, Lauren, primary, Xie, Jia, primary, Cho, Hyekyung P., primary, Twarog, Nathaniel, primary, Connelly, Michele, primary, Yan, Koon-Kiu, primary, Yu, Jiyang, primary, Porter, Shaina N., primary, Pruett-Miller, Shondra M., primary, Neale, Geoffrey, primary, Tinkle, Christopher L., primary, Federico, Sara M., primary, Stewart, Elizabeth A., primary, and Shelat, Anang A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents

Author

Gartrell, Jessica, primary, Mellado-Largarde, Marcia, primary, Clay, Michael R., primary, Bahrami, Armita, primary, Sahr, Natasha A., primary, Sykes, April, primary, Blankenship, Kaley, primary, Hoffmann, Lauren, primary, Xie, Jia, primary, Cho, Hyekyung P., primary, Twarog, Nathaniel, primary, Connelly, Michele, primary, Yan, Koon-Kiu, primary, Yu, Jiyang, primary, Porter, Shaina N., primary, Pruett-Miller, Shondra M., primary, Neale, Geoffrey, primary, Tinkle, Christopher L., primary, Federico, Sara M., primary, Stewart, Elizabeth A., primary, and Shelat, Anang A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma

Author

Furman, Wayne L., primary, Federico, Sara M., primary, McCarville, Mary Beth, primary, Shulkin, Barry L., primary, Davidoff, Andrew M., primary, Krasin, Matthew J., primary, Sahr, Natasha, primary, Sykes, April, primary, Wu, Jianrong, primary, Brennan, Rachel C., primary, Bishop, Michael William, primary, Helmig, Sara, primary, Stewart, Elizabeth, primary, Navid, Fariba, primary, Triplett, Brandon, primary, Santana, Victor M., primary, Bahrami, Armita, primary, Anthony, Gwendolyn, primary, Yu, Alice L., primary, Hank, Jacquelyn, primary, Gillies, Stephen D., primary, Sondel, Paul M., primary, Leung, Wing H., primary, and Pappo, Alberto S., primary

Published
2023
Full Text
View/download PDF

8. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists

Author

Iczkowski, Kenneth A., Egevad, Lars, Ma, Jun, Harding-Jackson, Nicholas, Algaba, Ferran, Billis, Athanase, Camparo, Philippe, Cheng, Liang, Clouston, David, Comperat, Eva M., Datta, Milton W., Evans, Andrew G., Griffiths, David F., Guo, Charles C., Hailemariam, Seife, Huang, Wei, Humphrey, Peter A., Jiang, Zhong, Kahane, Hillel, Kristiansen, Glen, La Rosa, Francisco G., Lopez-Beltran, Antonio, MacLennan, Gregory T., Magi-Galluzzi, Cristina, Merrimen, Jennifer, Montironi, Rodolfo, Osunkoya, Adeboye O., Picken, Maria M., Rao, Nagarjun, Shah, Rajal B., Shanks, Jonathan H., Shen, Steven S., Tawfik, Ossama W., True, Lawrence D., Van der Kwast, Theodorus, Varma, Murali, Wheeler, Thomas M., Zynger, Debra L., Sahr, Natasha, and Bostwick, David G.

Published
2014
Full Text
View/download PDF

9. SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents

Author

Gartrell, Jessica, primary, Mellado-Largarde, Marcia, additional, Clay, Michael R., additional, Bahrami, Armita, additional, Sahr, Natasha A., additional, Sykes, April, additional, Blankenship, Kaley, additional, Hoffmann, Lauren, additional, Xie, Jia, additional, Cho, Hyekyung P., additional, Twarog, Nathaniel, additional, Connelly, Michele, additional, Yan, Koon-Kiu, additional, Yu, Jiyang, additional, Porter, Shaina N., additional, Pruett-Miller, Shondra M., additional, Neale, Geoffrey, additional, Tinkle, Christopher L., additional, Federico, Sara M., additional, Stewart, Elizabeth A., additional, and Shelat, Anang A., additional

Published
2021
Full Text
View/download PDF

13. Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stress

Author

Gartrell, Jessica, primary, Mellado-Largarde, Marcia, additional, Martinez, Nancy E., additional, Clay, Michael R., additional, Bahrami, Armita, additional, Sahr, Natasha, additional, Sykes, April, additional, Blankenship, Kaley, additional, Hoffmann, Lauren, additional, Xie, Jia, additional, Plumley, Hyekyung, additional, Twarog, Nathaniel, additional, Connelly, Michele, additional, Yan, Koon-Kiu, additional, Yu, Jiyang, additional, Porter, Shaina N., additional, Pruett-Miller, Shondra M., additional, Neale, Geoffrey, additional, Tinkle, Christopher L., additional, Federico, Sara M., additional, Stewart, Elizabeth A., additional, and Shelat, Anang A., additional

Published
2020
Full Text
View/download PDF

15. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

Author

Federico, Sara M., primary, Pappo, Alberto S., additional, Sahr, Natasha, additional, Sykes, April, additional, Campagne, Olivia, additional, Stewart, Clinton F., additional, Clay, Michael R., additional, Bahrami, Armita, additional, McCarville, Mary B., additional, Kaste, Sue C., additional, Santana, Victor M., additional, Helmig, Sara, additional, Gartrell, Jessica, additional, Shelat, Anang, additional, Brennan, Rachel C., additional, Hawkins, Dana, additional, Godwin, Kimberly, additional, Bishop, Michael W., additional, Furman, Wayne L., additional, and Stewart, Elizabeth, additional

Published
2020
Full Text
View/download PDF

16. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing

Author

Riberdy, Janice M., primary, Zhou, Sheng, additional, Zheng, Fei, additional, Kim, Young-In, additional, Moore, Jennifer, additional, Vaidya, Abishek, additional, Throm, Robert E., additional, Sykes, April, additional, Sahr, Natasha, additional, Bonifant, Challice L., additional, Ryu, Byoung, additional, Gottschalk, Stephen, additional, and Velasquez, Mireya Paulina, additional

Published
2020
Full Text
View/download PDF

18. Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

Author

Nguyen, Rosa, primary, Sahr, Natasha, additional, Sykes, April, additional, McCarville, Mary Beth, additional, Federico, Sara M, additional, Sooter, Amanda, additional, Cullins, David, additional, Rooney, Barbara, additional, Janssen, William E, additional, Talleur, Aimee C, additional, Triplett, Brandon M, additional, Anthony, Gwendolyn, additional, Dyer, Michael A, additional, Pappo, Alberto S, additional, Leung, Wing H, additional, and Furman, Wayne L, additional

Published
2020
Full Text
View/download PDF

21. Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant

Author

Parikh, Suhag H., primary, Satwani, Prakash, additional, Ahn, Kwang Woo, additional, Sahr, Natasha A., additional, Fretham, Caitrin, additional, Abraham, Allistair A., additional, Agrawal, Vaibhav, additional, Auletta, Jeffery J., additional, Abdel-Azim, Hisham, additional, Copelan, Edward, additional, Diaz, Miguel-Angel, additional, Dvorak, Christopher C., additional, Frangoul, Haydar A., additional, Freytes, Cesar O., additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, George, Biju, additional, Gergis, Usama, additional, Hashmi, Shahrukh, additional, Hematti, Peiman, additional, Hildebrandt, Gerhard C., additional, Keating, Amy K., additional, Lazarus, Hillard M., additional, Myers, Kasiani C., additional, Olsson, Richard F., additional, Prestidge, Timothy, additional, Rotz, Seth J., additional, Savani, Bipin N., additional, Shereck, Evan B., additional, Williams, Kirsten M., additional, Wirk, Baldeep, additional, Pasquini, Marcelo C., additional, and Loren, Alison W., additional

Published
2019
Full Text
View/download PDF

22. Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)

Author

Parikh, Suhag, primary, Ahn, Kwang Woo, additional, Sahr, Natasha, additional, Zhu, Xiaochun, additional, Abraham, Allistair, additional, Auletta, Jeffery J., additional, Chhabra, Saurabh, additional, Copelan, Edward A., additional, Dvorak, Christopher C., additional, Fretham, Caitrin, additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, Gergis, Usama, additional, Heimatti, Peiman, additional, Hildebrandt, Gerhard C., additional, Keating, Amy K., additional, Myers, Kasiani C., additional, Savani, Bipin N., additional, Shah, Niketa C., additional, Pasquini, Marcelo C., additional, and Satwani, Prakash, additional

Published
2018
Full Text
View/download PDF

27. The Relationship Between Length of Stay and Readmissions in Bariatric Surgery Patients

Author

Lois, Alex W., Frelich, Matthew J., Sahr, Natasha A., Hohmann, Samuel F., Wang, Tao, and Gould, Jon C.

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Databases, Factual, Bariatric Surgery, Length of Stay, Middle Aged, Patient Readmission, Article, Patient Discharge, United States, Obesity, Morbid, Young Adult, Logistic Models, Outcome Assessment, Health Care, Humans, Female, Aged
Abstract

Hospital readmissions are a quality indicator in bariatric surgery. In recent years, duration of stay after bariatric surgery has trended down greatly. We hypothesized that a shorter postoperative hospitalization does not increase the likelihood of readmission.The University HealthSystem Consortium (UHC) is an alliance of academic medical centers and affiliated hospitals. The UHC's clinical database contains information on inpatient stay and returns (readmissions) up to 30 days after discharge. A multicenter analysis of outcomes was performed by the use of data from the January 2009 to December 2013 for patients 18 years and older. Patients were identified by bariatric procedure International Classification of Diseases, Ninth Revision, codes and restricted by diagnosis codes for morbid obesity.A total of 95,294 patients met inclusion criteria. The mean patient age was 45.4 (±0.11) years, and 73,941 (77.6%) subjects were female. There were 5,423 (5.7%) readmissions within the study period. Patients with hospitalizations of 3 days and more than 3 days were twice and four times as likely to be readmitted than those with hospitalizations of one day, respectively (P.001).Patients with longer postoperative hospitalizations were more likely to be readmitted after bariatric surgery. Early discharge does not appear to be associated with increased readmission rates.

Published
2015

30. Chromatin interactions and candidate genes at ten prostate cancer risk loci

Author

Du, Meijun, primary, Tillmans, Lori, additional, Gao, Jianzhong, additional, Gao, Ping, additional, Yuan, Tiezheng, additional, Dittmar, Rachel L, additional, Song, Wei, additional, Yang, Yuehong, additional, Sahr, Natasha, additional, Wang, Tao, additional, Wei, Gong-Hong, additional, Thibodeau, Stephen N., additional, and Wang, Liang, additional

Published
2016
Full Text
View/download PDF

31. 106 - Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)

Author

Parikh, Suhag, Ahn, Kwang Woo, Sahr, Natasha, Zhu, Xiaochun, Abraham, Allistair, Auletta, Jeffery J., Chhabra, Saurabh, Copelan, Edward A., Dvorak, Christopher C., Fretham, Caitrin, Gadalla, Shahinaz M., Gale, Robert Peter, Gergis, Usama, Heimatti, Peiman, Hildebrandt, Gerhard C., Keating, Amy K., Myers, Kasiani C., Savani, Bipin N., Shah, Niketa C., Pasquini, Marcelo C., and Satwani, Prakash

Published
2018
Full Text
View/download PDF

32. Depression, young age, chronic marijuana use, and interepisodic symptoms predict psychological distress in patients with cyclic vomiting syndrome.

Author

Taranukha, Tatyana, Charan Suresh Kumar, Vishnu, Seamon, Alex, Sahr, Natasha, Szabo, Aniko, and Venkatesan, Thangam

Subjects
DEPRESSION in children, MARIJUANA abuse, VOMITING in children, BRIEF Symptom Inventory, CHILD psychology
Abstract

Abstract: Background: Cyclic vomiting syndrome (CVS) is often triggered by stress. Patients report high degrees of psychological distress due to CVS, but there is limited data on factors associated with psychological distress. We sought to determine the degree of psychological distress and its correlation with clinical characteristics in CVS. Methods: The Brief Symptom Inventory (BSI), a validated tool to determine psychological distress, was administered prospectively to patients. The control population consisted of 719 normal subjects. Student's t test was used to compare means, and logistic regression analysis was performed to identify predictors of a GSI score ≥63, indicating high degrees of psychological distress. Scores for the regression predictors were calculated using the maximum likelihood estimate for the logistic regression model and was called the DAME score (depression, age 25‐35, chronic marijuana use, and interepisodic GI symptoms). Key Results: Of 87 patients, 60% were female, 92% were caucasian, and mean age was 37 years. Forty‐one percent of patients had high degrees of psychological distress with the highest scores for somatization. Independent predictors of psychological distress included depression, young age (25‐35 years), chronic marijuana use, and interepisodic dyspepsia (called the DAME score). A score of ≥7 accurately predicted psychological distress in >88% of patients. Conclusions & Inferences: Psychological distress is common in CVS and can be predicted accurately using our proposed DAME score. Whether psychological distress is a cause or an effect of CVS needs to be determined. Addressing psychological distress can potentially improve overall healthcare outcomes in CVS. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

33. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.

Author

Riberdy JM, Zhou S, Zheng F, Kim YI, Moore J, Vaidya A, Throm RE, Sykes A, Sahr N, Bonifant CL, Ryu B, Gottschalk S, and Velasquez MP

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with refractory/recurrent disease. We generated five lentiviral vectors encoding CD20, which may serve as a target for CAR T cell depletion, and 2 nd or 3 rd generation CD123-CARs since the benefit of two costimulatory domains is model dependent. Four CARs were based on the CD123-specific single-chain variable fragment (scFv) 26292 (292) and one CAR on the CD123-specific scFv 26716 (716), respectively. We designed CARs with different hinge/transmembrane (H/TM) domains and costimulatory domains, in combination with the zeta (z) signaling domain: 292.CD8aH/TM.41BBz (8.41BBz), 292.CD8aH/TM.CD28z (8.28z), 716.CD8aH/TM.CD28z (716.8.28z), 292.CD28H/TM. CD28z (28.28z), and 292.CD28H/TM.CD28.41BBz (28.28.41BBz). Transduction efficiency, expansion, phenotype, and target cell recognition of the generated CD123-CAR T cells did not significantly differ. CAR constructs were eliminated for the following reasons: (1) 8.41BBz CARs induced significant baseline signaling, (2) 716.8.28z CAR T cells had decreased anti-AML activity, and (3) CD28.41BBz CAR T cells had no improved effector function in comparison to CD28z CAR T cells. We selected the 28.28z CAR since CAR expression on the cell surface of transduced T cells was higher in comparison to 8.28z CARs. The clinical study (NCT04318678) evaluating 28.28z CAR T cells is now open for patient accrual., (© 2020 The Author(s).)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results